Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 412.5 GBX -1.43% Market Closed
Market Cap: 434.6m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

P/E
Price to Earnings

-3.1
Current
-2.8
Median
23
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-3.1
=
Market Cap
434.4m GBX
/
Net Income
-142m GBP
All Countries
Close
Market Cap P/E
UK
Oxford BioMedica PLC
LSE:OXB
434.4m GBP -3.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -179 080.5
US
Abbvie Inc
NYSE:ABBV
300.2B USD 59.1
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 37.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD -264.2
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 910.9
US
Epizyme Inc
F:EPE
94.1B EUR -477.1
AU
CSL Ltd
ASX:CSL
137.3B AUD 33.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 19
US
Seagen Inc
F:SGT
39.3B EUR -55.2
NL
argenx SE
XBRU:ARGX
34.1B EUR -129.5
Earnings Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average P/E: 212
Negative Multiple: -3.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 080.5 N/A
US
Abbvie Inc
NYSE:ABBV
59.1
412%
US
Amgen Inc
NASDAQ:AMGN
37.5
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -264.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -477.1 N/A
AU
CSL Ltd
ASX:CSL
33.5
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.5 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-10
2-Years Forward
P/E
-16.6
3-Years Forward
P/E
-103.5

See Also

Discover More